Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders-Reference-Cited by-同舟云学术

Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders

Published:2020-10-15 Issue:23 Volume:63 Page:14562-14575
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Chen Liqun¹,Chen Yanke¹,Zhang Chunyan¹,Jiao Bingyang¹,Liang Sheng¹,Tan Qiong¹,Chai Hongyu¹,Yu Weihua¹,Qian Yongzheng¹,Yang Hui¹,Yao Wuyi¹,Yu Jianguo¹,Luo Ying²,Plewe Michael²,Wang Jialiang²¹,Han Xiao-Ran²¹,Liu Jing²^ORCID

Affiliation:

1. Cullgen (Shanghai), Inc., 230 ChuanHong Road, Building 6, Chuansha, Pudong New Area, Shanghai 201202, People’s Republic of China

2. Cullgen Inc., 12671 High Bluff Drive Suite 130, San Diego, California 92130, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c01342

Reference71 articles.

1. Oncogenes in solid human tumours

2. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences

3. Molecular and biochemical characterization of the human trk proto-oncogene.

4. trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development.

5. trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent contributions of pyridazine as a privileged scaffold of anticancer agents in medicinal chemistry: An updated review;Bioorganic & Medicinal Chemistry;2024-09

2. Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor;European Journal of Medicinal Chemistry;2024-09

3. PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications;European Journal of Medicinal Chemistry;2024-09

4. Research progress of PROTACs for neurodegenerative diseases therapy;Bioorganic Chemistry;2024-06

5. Targeted degradation of zDHHC-PATs decreases substrate S-palmitoylation;PLOS ONE;2024-03-21